Saxenda is FDA-approved for obesity — but the details matter

What did @weightdoc actually say?

The creator's core argument is accurate and worth amplifying: Saxenda and Victoza are both liraglutide, and Wegovy and Ozempic are both semaglutide. The FDA-approved indication, not the molecule itself, determines whether a drug is "for diabetes" or "for obesity." The creator frames this as a correction to the popular narrative that people with obesity are "stealing medications" from people with diabetes.

That framing is fair. The confusion is real, and it causes genuine harm, stigmatizing patients who are using their prescribed, FDA-approved treatments. This video is a direct reply to someone who appears to have repeated a version of that narrative, and the creator's frustration comes through clearly.

Does the science back this up?

Yes, on the pharmacology, this is solid. Liraglutide (Victoza) was first approved by the FDA in 2010 for type 2 diabetes at doses up to 1.8 mg daily. Saxenda, also liraglutide but at a higher dose of up to 3.0 mg daily, received FDA approval for chronic weight management in 2014. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) established the evidence base for that obesity indication, showing roughly 8 percent body weight loss versus placebo over 56 weeks.

The semaglutide story is the same pattern. Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) was approved for type 2 diabetes in 2017. Wegovy (semaglutide 2.4 mg weekly) was approved for obesity in 2021, backed by the STEP 1 trial (Wilding et al., 2021, NEJM), which showed approximately 14.9 percent weight reduction versus placebo. Same molecule, different doses, different indications, different approvals.

What did they get wrong (or right)?

They got the pharmacology right. Where the video could have been more precise: the doses between paired products are not identical. Saxenda's obesity dose goes up to 3.0 mg, while Victoza caps at 1.8 mg for diabetes. Wegovy's approved dose is 2.4 mg weekly, while Ozempic's approved doses are lower. The creator says "exact same molecule," which is true, but the dosing differences matter clinically and contribute to why shortages in one product can, but do not automatically, affect the other.

The creator also glosses over why the same molecule can have two separate FDA approval pathways. That is not arbitrary. Each indication requires its own clinical trial data demonstrating safety and efficacy for that specific population and use case. Saying they are the "exact same medication" is close enough for a TikTok explainer but slightly imprecise for a clinical audience.

The closing line, "everybody has the right to a more healthy life," is advocacy, not medical information. That is fine for this context, but it is worth noting the video is making a normative argument, not just a scientific one.

What should you actually know?

The practical implication here matters for patients. If you are prescribed Wegovy for obesity, you are not using a diabetes drug off-label. You are using an FDA-approved obesity treatment. The same logic applies to Saxenda. These are distinct regulatory approvals, not workarounds.

That said, insurance coverage often treats them differently, and shortage dynamics are genuinely complex. During the Ozempic and Wegovy shortage period documented by the FDA between 2022 and 2024, the same manufacturing constraints affected both products despite their separate indications. So the "stealing medications" framing misreads how drug supply actually works, as the creator implies, but it is not entirely disconnected from real supply chain stress.

If your provider prescribes you a GLP-1 receptor agonist, the indication on your prescription matters for coverage, for dosing, and for monitoring. Ask your provider which product is approved for your specific condition.

Bottom line

This is one of the more accurate GLP-1 explainer videos circulating on TikTok right now. The creator correctly identifies a common misconception, applies real pharmacology, and names actual FDA approval timelines. The "exact same medication" framing is a minor oversimplification on dosing, but it does not distort the central claim. Worth sharing, with the caveat that dose and indication always matter in clinical practice.